Meoli et al. also gathered data from MASLD/NASH patients, revealing higher PKM2 serum levels and a twofold increase in inducible nitric oxide synthase (iNOS) gene expression levels in these patients. The gene discussed is NOS2; the disease is metabolic dysfunction-associated steatotic liver disease.